Core Viewpoint - Invivyd positions its monoclonal antibody VYD2311 as a potent alternative to COVID-19 vaccination, emphasizing its potential for "vaccine-free protection" against symptomatic COVID-19 [1] Company Focus and Pipeline - The company is advancing its REVOLUTION clinical program for VYD2311, continuing the commercialization of PEMGARDA, and exploring additional clinical indications, including long COVID and other infectious diseases like RSV and measles [2][13] - Invivyd has completed enrollment in the pivotal DECLARATION trial for VYD2311, with results expected in mid-2026 [6][9] Financial Performance - Invivyd raised over $200 million in the second half of 2025, ending the year with $226.7 million in cash, which supports operations through pivotal data expected in mid-2026 [4][17] - PEMGARDA's net revenues increased by 31% quarter-over-quarter and 25% year-over-year, totaling $53.4 million for the full year 2025, with a reorder rate of 77% among accounts [5][16] Clinical Trials and Safety Monitoring - The DECLARATION trial is a triple-blind randomized clinical trial evaluating VYD2311's safety and efficacy, with a target enrollment of approximately 1,770 subjects [6][7] - The Independent Data Monitoring Committee has reviewed early safety data and made recommendations regarding participant enrollment and monitoring [7][10] Commercial Strategy - Invivyd is seeing increased clinician interest in monoclonal antibodies for high-risk patients, with PEMGARDA included in guidelines from major health organizations [11][12] - The company is expanding its commercial footprint, with over 15,000 contracted GPO sites [5][14] Future Developments - Invivyd is excited to explore antibodies for long COVID and post-vaccination syndrome, with plans for updates on measles in the first half of the year [13][15]

Core Insights - Invivyd, Inc. reported strong financial results for Q4 and full year 2025, with significant revenue growth and reduced operating expenses, highlighting the potential commercialization of VYD2311 and ongoing clinical trials [2][4][12]. Financial Performance - Q4 2025 net product revenue from PEMGARDA reached $17.2 million, a 25% increase year-over-year and a 31% increase quarter-over-quarter [4][12]. - Full year 2025 net product revenue totaled $53.4 million, compared to $25.4 million in 2024 [12]. - Cash and cash equivalents at year-end 2025 were $226.7 million, bolstered by over $200 million raised in financing during the second half of 2025 [4][12]. - Research and Development (R&D) expenses decreased to $38.3 million in 2025 from $137.3 million in 2024, primarily due to lower contract research costs [12]. - Selling, General & Administrative (SG&A) expenses increased to $66.9 million in 2025 from $63.4 million in 2024, attributed to higher personnel-related costs [12]. - The net loss for 2025 was $52.5 million, significantly reduced from $169.9 million in 2024, with a net loss per share of $0.30 compared to $1.43 in the previous year [12][36]. Clinical and Regulatory Developments - The DECLARATION Phase 3 pivotal clinical trial for VYD2311 has achieved full enrollment, with top-line data expected in mid-2026 [4][5]. - The FDA granted Fast Track designation for VYD2311 in December 2025, facilitating expedited development and review processes [5][7]. - The Independent Data Monitoring Committee (IDMC) recommended allowing pregnant and breastfeeding women to enroll in the DECLARATION trial after reviewing unblinded safety data [5]. - The LIBERTY Phase 3 clinical trial will assess the safety and immunologic profile of VYD2311 compared to mRNA COVID vaccines, with specific monitoring for adverse events of interest [5][7]. Pipeline Expansion - Invivyd is advancing its pipeline with VBY329, a monoclonal antibody candidate for the prevention of Respiratory Syncytial Virus (RSV) in children, expected to enter IND readiness in the second half of 2026 [7][12]. - The company is also planning a Phase 2 clinical trial for VYD2311 in individuals with Long COVID or COVID vaccine injury, anticipated to start by mid-2026 [7]. Corporate Updates - Michael Mina, M.D., Ph.D., has been appointed as Chief Medical Officer, indicating a strategic move to enhance clinical leadership [12]. - Invivyd is launching a national multimedia educational campaign in partnership with Lindsey Vonn to raise public awareness about the role of antibodies in disease prevention [12].

Core Insights - Tonix Pharmaceuticals is developing TNX-4800, a long-acting human monoclonal antibody targeting Borrelia burgdorferi, the causative agent of Lyme disease, with plans for clinical trials to begin in early 2027 [1][2][3] Group 1: Product Development - TNX-4800 is designed for annual seasonal use, administered subcutaneously in the spring to provide protection against Lyme disease throughout the tick season [1][3] - The company plans to meet with the FDA in 2026 to discuss Phase 2/3 development options, including a controlled human infection model (CHIM) study [2] - TNX-4800 has shown 95% effectiveness in preventing infection in non-human primates after exposure to infected ticks [3] Group 2: Market Potential - Approximately 70 million people in the U.S. living in Lyme disease-endemic areas could benefit from TNX-4800 as a pre-exposure prophylactic [1] - There are currently no FDA-approved vaccines or prophylactics available for Lyme disease in the U.S., highlighting a significant market opportunity for TNX-4800 [1][2] Group 3: Safety and Efficacy - TNX-4800 demonstrated rapid systemic absorption, with serum concentrations remaining quantifiable for over 200 days in 80% of volunteers at the lowest dose [4][5] - The mean half-life of TNX-4800 ranged from 62 to 69 days across different dosage groups, indicating prolonged efficacy [4] - Most adverse events reported were mild or moderate, and TNX-4800 was generally well tolerated [5] Group 4: Lyme Disease Overview - Lyme disease is the most common vector-borne infection in the U.S., with increasing incidence, particularly in the Northeast, mid-Atlantic, and upper-Midwest regions [6] - Typical symptoms include fever, headache, fatigue, and a characteristic skin rash, with untreated cases potentially leading to severe complications [6]

Core Insights - Tonix Pharmaceuticals has in-licensed worldwide rights to TNX-4800, a long-acting human monoclonal antibody targeting the outer surface protein A (OspA) of Borrelia burgdorferi, the causative agent of Lyme disease [2][3] - TNX-4800 is designed for annual seasonal use, with a single subcutaneous dose providing protection against Lyme disease for the entire tick season in the U.S. [2][3] - The company aims to advance TNX-4800 through additional clinical trials, with the goal of submitting a Biologics Licensing Application (BLA) [3][8] Company Overview - Tonix Pharmaceuticals is a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, focusing on central nervous system disorders, immunology, immuno-oncology, and infectious diseases [8] - The company recently received FDA approval for Tonmya, a non-opioid analgesic for fibromyalgia, marking the first approval for a new prescription medicine for this condition in over 15 years [8] - Tonix's infectious disease portfolio includes TNX-801, a vaccine in development for mpox and smallpox, and TNX-4200, a broad-spectrum antiviral agent [8] Industry Context - Lyme disease is the most common vector-borne infection in the U.S., with its incidence increasing annually [3] - Approximately 70 million people in the U.S. live in areas where Lyme disease is endemic, highlighting the urgent public health need for effective prophylactic measures [2][3] - Current preventive measures for Lyme disease are limited, as there are no FDA-approved vaccines or prophylactics available [2][3]